Siegfried Reich - Feb 9, 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc. (TPTX)

Role
EVP & Chief Scientific Officer
Signature
/s/ Paolo Tombesi, Attorney-in-Fact
Stock symbol
TPTX
Transactions as of
Feb 9, 2022
Transactions value $
-$14,411
Form type
4
Date filed
2/11/2022, 05:10 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Sale -$14.4K -397 -10.33% $36.30 3.45K Feb 9, 2022 Direct F1
transaction TPTX Common Stock Award $0 +13.6K +393.47% $0.00 17K Feb 9, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +48.8K $0.00 48.8K Feb 9, 2022 Common Stock 48.8K $37.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2 Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F3 1/48th of the shares vest monthly following February 9, 2022.